The Influence of Timing of Cabergoline Initiation on Prevention of OHSS
NCT02620605
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
75
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
DRUG:
Late Cabergoline 0.5mg
DRUG:
Early Cabergoline 0.5mg
Sponsor
Mona M Shaban